Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report

Onkologie. 2005 Dec;28(12):653-6. doi: 10.1159/000089146. Epub 2005 Dec 1.

Abstract

Background: Sinonasal Teratocarcinosarcoma (SNTC) is a very unusual and aggressive neoplasm characterized by the combination of malignant teratoma and carcinosarcoma features. We present the first case of malignant SNTC treated with individualized multimodal therapy including a histology-specific chemotherapy.

Case report: A 31-year-old man presented with an obstruction of the right pansinus. Histology showed an SNTC with major parts of small cell, poorly differentiated carcinoma and a small proportion of highly differentiated embryonal rhabdomyosarcoma. An operation was performed followed by intraoperative application of a 5-FU ointment. Adjuvant chemotherapy with cisplatin, etoposid and ifosfamid were given in regard to the major components of this heterogeneous tumor. Radiotherapy up to 59.4 Gy was applied.

Conclusion: 36 months after the end of therapy, there is no sign of tumor recurrence or metastasis in our patient. We suggest that surgery, radiotherapy and a histology-specific multidrug chemotherapy seems to be a therapeutic approach that is appropriate for this heterogeneous tumor.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinosarcoma / pathology
  • Carcinosarcoma / therapy*
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Etoposide / therapeutic use
  • Fluorouracil / therapeutic use
  • General Surgery
  • Humans
  • Ifosfamide / therapeutic use
  • Male
  • Nose Neoplasms / pathology
  • Nose Neoplasms / therapy*
  • Paranasal Sinus Neoplasms / pathology
  • Paranasal Sinus Neoplasms / therapy*
  • Radiotherapy, Adjuvant
  • Teratocarcinoma / pathology
  • Teratocarcinoma / therapy*
  • Treatment Outcome

Substances

  • Etoposide
  • Cisplatin
  • Fluorouracil
  • Ifosfamide